Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2.[1][2] As of May 2017[update], it is in Phase II clinical trials for the treatment of diabetic macular edema.[3][4]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Angiopoietin 2 |
Clinical data | |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
|
IUPHAR/BPS |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C6440H9966N1722O2008S38 |
Molar mass | 144860.89 g·mol−1 |
This drug is being developed by Regeneron Pharmaceuticals.[citation needed]